Prevalence of five pharmacologically most important CYP2C9 and CYP2C19 allelic variants in the population from the Republic of Srpska in Bosnia and Herzegovina

1Sim SC, Kacevska M, Ingelman-Sundberg M. Pharmacogenomics of drug-metabolizing enzymes: A recent update on clinical implications and endogenous effects. Pharmacogenomics J 2013;13:1–11. doi: 10.1038/tpj.2012.45Sim SC Kacevska M Ingelman-Sundberg M Pharmacogenomics of drug-metabolizing enzymes: A recent update on clinical implications and endogenous effects Pharmacogenomics J 2013 131 11 10.1038/tpj.2012.4523089672Open DOISearch in Google Scholar

2Mustafa G, Nandekar PP, Bruce NJ, Wade RC. Differing membrane interactions of two highly similar drug-metabolizing cytochrome P450 isoforms: CYP 2C9 and CYP 2C19. Int J Mol Sci 2019;20:4328. doi: 10.3390/ijms20184328Mustafa G Nandekar PP Bruce NJ Wade RC Differing membrane interactions of two highly similar drug-metabolizing cytochrome P450 isoforms: CYP 2C9 and CYP 2C19 Int J Mol Sci 2019 204328 10.3390/ijms20184328677066131487853Open DOISearch in Google Scholar

3Sim SC, Altman RB, Ingelman-Sundberg M. Databases in the area of pharmacogenetics. Hum Mutat 2011;32:526–31. doi: 10.1002/humu.21454Sim SC Altman RB Ingelman-Sundberg M Databases in the area of pharmacogenetics Hum Mutat 2011 32526 31 10.1002/humu.21454335202721309040Open DOISearch in Google Scholar

4Raunio H. Modeling of interactions between xenobiotics and cytochrome P450 (CYP) enzymes. Front Pharmacol 2015;6:123. doi: 10.3389/fphar.2015.00123Raunio H Modeling of interactions between xenobiotics and cytochrome P450 (CYP) enzymes Front Pharmacol 2015 6123 10.3389/fphar.2015.00123446416926124721Open DOISearch in Google Scholar

5Subramanian M, Agrawal V, Sandee D, Tam HK, Miller WL, Tracy TS. Effect of P450 oxidoreductase variants on the metabolism of model substrates mediated by CYP2C9.1, CYP2C9.2, and CYP2C9.3. Pharmacogenet Genomics 2012;22:590–7. doi: 10.1097/FPC.0b013e3283544062Subramanian M Agrawal V Sandee D Tam HK Miller WL Tracy TS Effect of P450 oxidoreductase variants on the metabolism of model substrates mediated by CYP2C9.1, CYP2C9.2, and CYP2C9.3 Pharmacogenet Genomics 2012 22590 7 10.1097/FPC.0b013e328354406222547083Open DOISearch in Google Scholar

6Wu AHB. Drug metabolizing enzyme activities versus genetic variances for drug of clinical pharmacogenomic relevance. Clin Proteomics 2011;8:12. doi: 10.1186/15590275-8-12Wu AHB Drug metabolizing enzyme activities versus genetic variances for drug of clinical pharmacogenomic relevance Clin Proteomics 2011 812 10.1186/15590275-8-12Open DOISearch in Google Scholar

7Shirasaka Y, Chaudhry AS, McDonald M, Prasad B, Wong T, Calamia JC, Fohner A, Thornton TA, Isoherranen N, Unadkat JD, Rettie AE, Schuetz EG, Thummel KE. Interindividual variability of CYP2C19-catalyzed drug metabolism due to differences in gene diplotypes and cytochrome P450 oxidoreductase content. Pharmacogenomics J 2016;16:375–87. doi: 10.1038/tpj.2015.58Shirasaka Y Chaudhry AS McDonald M Prasad B Wong T Calamia JC Fohner A Thornton TA Isoherranen N Unadkat JD Rettie AE Schuetz EG Thummel KE Interindividual variability of CYP2C19-catalyzed drug metabolism due to differences in gene diplotypes and cytochrome P450 oxidoreductase content Pharmacogenomics J 2016 16375 87 10.1038/tpj.2015.58477543626323597Open DOISearch in Google Scholar

8Ganoci L, Božina T, Mirošević Skvrce N, Lovrić M, Mas P, Božina N. Genetic polymorphisms of cytochrome P450 enzymes: CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5 in the Croatian population. Drug Metab Pers Ther 2017;32:11–21. doi: 10.1515/dmpt-2016-0024Ganoci L Božina T Mirošević Skvrce N Lovrić M Mas P Božina N Genetic polymorphisms of cytochrome P450 enzymes: CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5 in the Croatian population Drug Metab Pers Ther 2017 3211 21 10.1515/dmpt-2016-002428272018Open DOISearch in Google Scholar

9Theken KN, Lee CR, Gong L, Caudle KE, Formea CM, Gaedigk A, Klein TE, Agúndez JAG, Grosser T. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2C9 and nonsteroidal anti-inflammatory drugs. Clin Pharmacol Ther 2020;108:191–200. doi: 10.1002/cpt.1830Theken KN Lee CR Gong L Caudle KE Formea CM Gaedigk A Klein TE Agúndez JAG Grosser T Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2C9 and nonsteroidal anti-inflammatory drugs Clin Pharmacol Ther 2020 108191 200 10.1002/cpt.1830808088232189324Open DOISearch in Google Scholar

10Kirchheiner J, Brockmöller J. Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin Pharmacol Ther 2005;77:1–16. doi: 10.1016/j.clpt.2004.08.009Kirchheiner J Brockmöller J Clinical consequences of cytochrome P450 2C9 polymorphisms Clin Pharmacol Ther 2005 771 16 10.1016/j.clpt.2004.08.00915637526Open DOISearch in Google Scholar

11Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: Pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 2007;116:496–526. doi: 10.1016/j.pharmthera.2007.09.004Ingelman-Sundberg M Sim SC Gomez A Rodriguez-Antona C Influence of cytochrome P450 polymorphisms on drug therapies: Pharmacogenetic, pharmacoepigenetic and clinical aspects Pharmacol Ther 2007 116496 526 10.1016/j.pharmthera.2007.09.00418001838Open DOISearch in Google Scholar

12Šupe S, Poljaković Z, Božina T, Ljevak J, Macolić Šarinić V, Božina N. Clinical application of genotype-guided dosing of warfarin in patients with acute stroke. Arch Med Res 2015;46:265–73. doi: 10.1016/j.arcmed.2015.05.001Šupe S Poljaković Z Božina T Ljevak J Macolić Šarinić V Božina N Clinical application of genotype-guided dosing of warfarin in patients with acute stroke Arch Med Res 2015 46265 73 10.1016/j.arcmed.2015.05.00125989350Open DOISearch in Google Scholar

13Shendre A, Dillon C, Limdi NA. Pharmacogenetics of warfarin dosing in patients of African and European ancestry. Pharmacogenomics 2018;19:1357–71. doi: 10.2217/pgs-2018-0146Shendre A Dillon C Limdi NA Pharmacogenetics of warfarin dosing in patients of African and European ancestry Pharmacogenomics 2018 191357 71 10.2217/pgs-2018-0146656276430345882Open DOISearch in Google Scholar

14El Rouby N, Lima JJ, Johnson JA. Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine. Expert Opin Drug Metab Toxicol 2018;14:447–60. doi: 10.1080/17425255.2018.1461835El Rouby N Lima JJ Johnson JA Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine Expert Opin Drug Metab Toxicol 2018 14447 60 10.1080/17425255.2018.1461835594215429620484Open DOISearch in Google Scholar

15Janha RE, Worwui A, Linton KJ, Shaheen SO, Sisay-Joof F, Walton RT. Inactive alleles of cytochrome P450 2C19 may be positively selected in human evolution. BMC Evol Biol 2014;14:71. doi: 10.1186/1471-2148-14-71Janha RE Worwui A Linton KJ Shaheen SO Sisay-Joof F Walton RT Inactive alleles of cytochrome P450 2C19 may be positively selected in human evolution BMC Evol Biol 2014 1471 10.1186/1471-2148-14-71403653224690327Open DOISearch in Google Scholar

16Dehbozorgi M, Kamalidehghan B, Hosseini I, Dehghanfard Z, Sangtarash MH, Firoozi M, Ahmadipour F, Meng GY, Houshmand M. Prevalence of the CYP2C19*2 (681 G>A), *3 (636 G>A) and *17 (-806 C>T) alleles among an Iranian population of different ethnicities. Mol Med Rep 2018;17:4195–202. doi: 10.3892/mmr.2018.8377Dehbozorgi M Kamalidehghan B Hosseini I Dehghanfard Z Sangtarash MH Firoozi M Ahmadipour F Meng GY Houshmand M Prevalence of the CYP2C19*2 (681 G>A), *3 (636 G>A) and *17 (-806 C>T) alleles among an Iranian population of different ethnicities Mol Med Rep 2018 174195 202 10.3892/mmr.2018.8377580219029328413Open DOISearch in Google Scholar

17Jakovski K, Nestorovska AK, Labacevski N, Dimovski AJ. Characterization of the most common CYP2C9 and CYP2C19 allelic variants in the population from the Republic of Macedonia. Pharmazie 2013;68:893–8. PMID: 24380239Jakovski K Nestorovska AK Labacevski N Dimovski AJ Characterization of the most common CYP2C9 and CYP2C19 allelic variants in the population from the Republic of Macedonia Pharmazie 2013 68893 8 PMID: 24380239Search in Google Scholar

18Hicks JK, Sangkuhl K, Swen JJ, Ellingrod VL, Müller DJ, Shimoda K, Bishop JR, Kharasch ED, Skaar TC, Gaedigk A, Dunnenberger HM, Klein TE, Caudle KE, Stingl JC. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther 2017;102:37–44. doi: 10.1002/cpt.597Hicks JK Sangkuhl K Swen JJ Ellingrod VL Müller DJ, Shimoda K Bishop JR Kharasch ED Skaar TC Gaedigk A Dunnenberger HM Klein TE Caudle KE Stingl JC Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update Clin Pharmacol Ther 2017 10237 44 10.1002/cpt.597547847927997040Open DOISearch in Google Scholar

19Hicks JK, Bishop JR, Sangkuhl K, Muller DJ, Ji Y, Leckband SG, Leeder JS, Graham RL, Chiulli DL, LLerena A, Skaar TC, Scott SA, Stingl JC, Klein TE, Caudle KE, Gaedigk A. Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin Pharmacol Ther 2015;98:127–34. doi: 10.1002/cpt.147Hicks JK Bishop JR Sangkuhl K Muller DJ Ji Y Leckband SG Leeder JS Graham RL Chiulli DL LLerena A, Skaar TC Scott SA Stingl JC Klein TE Caudle KE Gaedigk A Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors Clin Pharmacol Ther 2015 98127 34 10.1002/cpt.147451290825974703Open DOISearch in Google Scholar

20Burian M, Grösch S, Tegeder I, Geisslinger G. Validation of a new fluorogenic real-time PCR assay for detection of CYP2C9 allelic variants and CYP2C9 allelic distribution in a German population. Br J Clin Pharmacol 2002;54:518–21. doi: 10.1046/j.1365-2125.2002.01693.xBurian M Grösch S Tegeder I Geisslinger G Validation of a new fluorogenic real-time PCR assay for detection of CYP2C9 allelic variants and CYP2C9 allelic distribution in a German population Br J Clin Pharmacol 2002 54518 21 10.1046/j.1365-2125.2002.01693.x187448012445031Open DOISearch in Google Scholar

21Republika Srpska I of S. Population estimates, annual rellease 2013–2019. 2020;158(20):1.Republika Srpska I of S Population estimates annual rellease 2013–2019 2020 158 20 1Search in Google Scholar

22Gaikovitch EA, Cascorbi I, Mrozikiewicz PM, Brockmöller J, Frötschl R, Köpke K, Gerloff T, Chernov JN, Roots I. Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population. Eur J Clin Pharmacol 2003;59:303–12. doi: 10.1007/s00228-003-0606-2Gaikovitch EA Cascorbi I Mrozikiewicz PM Brockmöller J Frötschl R Köpke K, Gerloff T Chernov JN Roots I Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population Eur J Clin Pharmacol 2003 59303–12 10.1007/s00228-003-0606-212879168Open DOISearch in Google Scholar

23Dorado P, Berecz R, Norberto MJ, Yasar Ü, Dahl ML, LLerena A. CYP2C9 genotypes and diclofenac metabolism in Spanish healthy volunteers. Eur J Clin Pharmacol 2003;59:221–5. doi: 10.1007/s00228-003-0588-0Dorado P Berecz R Norberto MJ Yasar Ü Dahl ML LLerena A CYP2C9 genotypes and diclofenac metabolism in Spanish healthy volunteers Eur J Clin Pharmacol 2003 59221 5 10.1007/s00228-003-0588-012734606Open DOISearch in Google Scholar

24Arvanitidis K, Ragia G, Iordanidou M, Kyriaki S, Xanthi A, Tavridou A, Manolopoulos VG. Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population. Fundam Clin Pharmacol 2 0 0 7 ; 2 1 : 4 1 9 – 2 6 . doi: 10.1111/j.1472-8206.2007.00510.xArvanitidis K Ragia G Iordanidou M Kyriaki S Xanthi A Tavridou A Manolopoulos VG Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population Fundam Clin Pharmacol 2 0 0 7 ; 2 1 : 4 1 9 – 2 6 10.1111/j.1472-8206.2007.00510.x17635181Open DOISearch in Google Scholar

25Skadrić I, Stojković O. Defining screening panel of functional variants of CYP1A1, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 genes in Serbian population. Int J Legal Med 2019;134:433–9. doi: 10.1007/s00414-019-02234-7Skadrić I Stojković O Defining screening panel of functional variants of CYP1A1, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 genes in Serbian population Int J Legal Med 2019 134433 9 10.1007/s00414-019-02234-731858263Open DOISearch in Google Scholar

26Herman D, Dolžan V, Breskvar K. Genetic polymorphism of cytochromes P450 2C9 and 2C19 in Slovenian population. Zdr Vestn 2003;72:347–51.Herman D Dolžan V Breskvar K Genetic polymorphism of cytochromes P450 2C9 and 2C19 in Slovenian population Zdr Vestn 2003 72347 51Search in Google Scholar

27Buzoianu AD, Militaru FC, Vesa ŞC, Trifa AP, Crişan S. The impact of the CYP2C9 and VKORC1 polymorphisms on acenocoumarol dose requirements in a Romanian population. Blood Cells Mol Dis 2013;50:166–70. doi: 10.1016/j.bcmd.2012.10.010Buzoianu AD Militaru FC Vesa ŞC Trifa AP Crişan S The impact of the CYP2C9 and VKORC1 polymorphisms on acenocoumarol dose requirements in a Romanian population Blood Cells Mol Dis 2013 50166 70 10.1016/j.bcmd.2012.10.01023159639Open DOISearch in Google Scholar

28Sistonen J, Fuselli S, Palo JU, Chauhan N, Padh H, Sajantila A. Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scales. Pharmacogenet Genomics 2009;19:170–9. doi: 10.1097/ FPC.0b013e32831ebb30Sistonen J Fuselli S Palo JU Chauhan N Padh H Sajantila A Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scales Pharmacogenet Genomics 2009 19170 9 10.1097/FPC.0b013e32831ebb3019151603Open DOISearch in Google Scholar

29Johnson JA, Caudle KE, Gong L, Whirl-Carrillo M, Stein CM, Scott SA, Lee MT, Gage BF, Kimmel SE, Perera MA, Anderson JL, Pirmohamed M, Klein TE, Limdi NA, Cavallari LH, Wadelius M. Clinical pharmacogenetics implementation consortium (CPIC) guideline for pharmacogenetics-guided warfarin dosing: 2017 update. Clin Pharmacol Ther 2017; 102:397–404. doi: 10.1002/cpt.668Johnson JA Caudle KE Gong L Whirl-Carrillo M Stein CM Scott SA Lee MT Gage BF Kimmel SE Perera MA Anderson JL Pirmohamed M Klein TE Limdi NA Cavallari LH Wadelius M Clinical pharmacogenetics implementation consortium (CPIC) guideline for pharmacogenetics-guided warfarin dosing: 2017 update Clin Pharmacol Ther 2017 102397 404 10.1002/cpt.668554694728198005Open DOISearch in Google Scholar

30Krasniqi V, Dimovski A, Bytyqi HQ, Eftimov A, Šimičevic L, Božina N. Genetic polymorphisms of CYP2C9, CYP2C19, and CYP3A5 in Kosovar population. Arh Hig Rada Toksikol 2017;68:180–4. doi: 10.1515/aiht-2017-68-2998Krasniqi V Dimovski A Bytyqi HQ Eftimov A Šimičevic L Božina N Genetic polymorphisms of CYP2C9, CYP2C19, and CYP3A5 in Kosovar population Arh Hig Rada Toksikol 2017 68180 4 10.1515/aiht-2017-68-299828976882Open DOISearch in Google Scholar

31Bathum L, Andersen-Ranberg K, Boldsen J, Brøsen K, Jeune B. Genotypes for the cytochrome p450 enzymes CYP2D6 and CYP2C19 in human longevity. Role of CYP2D6 and CYP2C19 in longevity. Eur J Clin Pharmacol 1998;54:427–30. doi: 10.1007/s002280050487Bathum L Andersen-Ranberg K Boldsen J Brøsen K Jeune B Genotypes for the cytochrome p450 enzymes CYP2D6 and CYP2C19 in human longevity Role of CYP2D6 and CYP2C19 in longevity. Eur J Clin Pharmacol 1998 54427–30 10.1007/s0022800504879754988Open DOISearch in Google Scholar

32Jurima-Romet M, Goldstein JA, LeBelle M, Aubin RA, Foster BC, Walop W, Rode A. CYP2C19 genotyping and associated mephenytoin hydroxylation polymorphism in a Canadian Inuit population. Pharmacogenetics 1996;6:329–39. doi: 10.1097/00008571-199608000-00006Jurima-Romet M Goldstein JA LeBelle M Aubin RA Foster BC Walop W Rode A CYP2C19 genotyping and associated mephenytoin hydroxylation polymorphism in a Canadian Inuit population Pharmacogenetics 1996 6329–39 10.1097/00008571-199608000-000068873219Open DOISearch in Google Scholar

33Brockmöller J, Rost K, Gross D, Schenkel A, Roots I. Phenotyping of CYP2C19 with enantiospecific HPLC quantification of R and S mephenytoin and comparison with the intron4/exon5 G >A splice site mutation. Pharmacogenetics 1995;5:80–8. doi: 10.1097/00008571-199504000-00004Brockmöller J Rost K Gross D Schenkel A Roots I Phenotyping of CYP2C19 with enantiospecific HPLC quantification of R and S mephenytoin and comparison with the intron4/exon5 G >A splice site mutation Pharmacogenetics 1995 580 8 10.1097/00008571-199504000-000047663532Open DOISearch in Google Scholar

34Kurzawski M, Gawrońska-Szklarz B, Wrześniewska J, Siuda A, Starzyńska T, Droździk M. Effect of CYP2C19*17 gene variant on Helicobacter pylori eradication in peptic ulcer patients. Eur J Clin Pharmacol 2006;62:877–80. doi: 10.1007/s00228-006-0183-2Kurzawski M Gawrońska-Szklarz B Wrześniewska J Siuda A Starzyńska T Droździk M Effect of CYP2C19*17 gene variant on Helicobacter pylori eradication in peptic ulcer patients Eur J Clin Pharmacol 2006 62877 80 10.1007/s00228-006-0183-216912869Open DOISearch in Google Scholar

35Hoskins JM, Shenfield GM, Gross AS. Relationship between proguanil metabolic ratio and CYP2C19 genotype in a Caucasian population. Br J Clin Pharmacol 1998;45:499–504. doi: 10.1046/j.1365-2125.1998.00807.xHoskins JM Shenfield GM Gross AS Relationship between proguanil metabolic ratio and CYP2C19 genotype in a Caucasian population Br J Clin Pharmacol 1998 45499–504 10.1046/j.1365-2125.1998.00807.x18736909833604Open DOISearch in Google Scholar

36Ašić A, Salazar R, Storm N, Doğan S, Höppner W, Marjanović D, Primorac D. Population study of thrombophilic markers and pharmacogenetic markers of warfarin prevalence in Bosnia and Herzegovina. Croat Med J 2019;60:212–20. doi: 10.3325/cmj.2019.60.212Ašić A Salazar R Storm N Doğan S Höppner W Marjanović D Primorac D Population study of thrombophilic markers and pharmacogenetic markers of warfarin prevalence in Bosnia and Herzegovina Croat Med J 2019 60212 20 10.3325/cmj.2019.60.212Open DOISearch in Google Scholar

37Semiz S, Dujić T, Ostanek B, Prnjavorac B, Bego T, Malenica M. Analysis of CYP2C9*2, CYP2C19*2, and CYP2D6*4 polymorphisms in patients with type 2 diabetes mellitus. Bosn J BASIC Med Sci 2010;10:287–91. doi: 10.17305/bjbms.2010.2662Semiz S Dujić T Ostanek B Prnjavorac B Bego T Malenica M Analysis of CYP2C9*2, CYP2C19*2, and CYP2D6*4 polymorphisms in patients with type 2 diabetes mellitus Bosn J BASIC Med Sci 2010 10287 91 10.17305/bjbms.2010.2662548903621108610Open DOISearch in Google Scholar

38Božina N, Granić P, Lalić Z, Tramišak I, Lovrić M, Stavljenić-Rukavina A. Genetic polymorphisms of cytochromes P450: CYP2C9, CYP2C19, and CYP2D6 in Croatian population. Croat Med J 2003;44:425–8. PMID: 12950145Božina N Granić P Lalić Z Tramišak I Lovrić M Stavljenić-Rukavina A Genetic polymorphisms of cytochromes P450: CYP2C9, CYP2C19, and CYP2D6 in Croatian population Croat Med J 2003 44425 8 PMID: 12950145Search in Google Scholar

39Herman D, Locatelli I, Grabnar I, Peternel P, Stegnar M, Mrhar A, Breskvar K, Dolzan V. Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose. Pharmacogenomics J 2005;5:193–202. doi: 10.1038/sj.tpj.6500308Herman D Locatelli I Grabnar I Peternel P Stegnar M Mrhar A Breskvar K Dolzan V Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose Pharmacogenomics J 2005 5193 202 10.1038/sj.tpj.650030815824753Open DOISearch in Google Scholar

40Arici M, Özhan G. CYP2C9, CYPC19 and CYP2D6 gene profiles and gene susceptibility to drug response and toxicity in Turkish population. Saudi Pharm J 2017;25:376–80. doi: 10.1016/j.jsps.2016.09.003Arici M Özhan G CYP2C9, CYPC19 and CYP2D6 gene profiles and gene susceptibility to drug response and toxicity in Turkish population Saudi Pharm J 2017 25376 80 10.1016/j.jsps.2016.09.003535709828344492Open DOISearch in Google Scholar

41Scordo MG, Caputi AP, D’Arrigo C, Fava G, Spina E. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population. Pharmacol Res 2004;50:195–200. doi: 10.1016/j.phrs.2004.01.004Scordo MG Caputi AP D’Arrigo C, Fava G Spina E Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population Pharmacol Res 2004 50195 200 10.1016/j.phrs.2004.01.00415177309Open DOISearch in Google Scholar